Drug Trend: Hepatitis C Pills Driving U.S. Drug Costs Up, Highest and Fastest in 10 Years

According to Express Scripts, it is proven that the highly effective but expensive new pills to treat hepatitis C which drove a 13.1 percent increase in the U.S. prescription drug spending in 2014 which has been also recorded as the fastest rate of increase in more than a decade.

The company, which is known to be the biggest U.S. manager of pharmacy benefits and administers pharmaceutical care for many leading employers worldwide, has warned frequently about the runaway cost of new medicines now reaching the market.

As being reported on last Tuesday, its 2014 drug trend report has shown that spending on specialty drugs, including conditions like cancer, multiple sclerosis as well as hepatitis C, made up more than 31 percent of drug expenditure last year.

Mr. Glen Stettin was asked to give a statement or any comment regarding the drive surge for the Hepatitis C pills in the United States Drug costs. “For the past several years, annual drug spending increases have been below the annual rate of overall healthcare inflation in the U.S., but that paradigm is shifting dramatically as prices for medications increase at an unprecedented and unsustainable rate,” as stated by Mr. Glen Stettin, the Express Scripts senior vice president of clinical, research and new solutions.

According to Express Scripts, the United States already spent 743 percent more on hepatitis C drugs in 2014 than in 2013 along with the arrival of new pills namely, Harvoni and Sovaldi from Gilead Sciences and Viekira Pak from Abbvie.

Furthermore, it has been known that the upcoming innovations which include a wave of different novel immune-system boosting cancer drugs and the so-called PCSK9 inhibitors for high cholesterol levels in the body will continue to challenge the United States especially for promoting wellness of mankind.

Health is very expensive to maintain if we don’t watch we eat and drink.

 

facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *